| In Focus |
spotlight on the march 5 issue.
- Gross, Robert, MD, PhD, Editor-in-Chief, Neurology. Pages: 873
|
| Editorial |
what is the nih toolbox, and what will it mean to neurology?.
- Bleck, Thomas, MD, FCCM, Nowinski, Cindy, PhD, MD, Gershon, Richard, Koroshetz, Walter. Pages: 874-875
|
can "dissemination" include the pns in adults with acute disseminated encephalomyelitis?.
- Naismith, Robert, Banwell, Brenda. Pages: 876-877
|
backwaters and rapids on the amyloid river.
- Burns, Jeffrey, MD, MS, Swerdlow, Russell. Pages: 878-879
|
pediatric neurohospitalists: an idea that has come of age?.
- Schor, Nina, MD, PhD, Carlson, Douglas. Pages: 880-881
|
| Article |
postinfectious neurologic syndromes: a prospective cohort study.
- Marchioni, Enrico, Ravaglia, Sabrina, MD, PhD, Montomoli, Cristina, Tavazzi, Eleonora, Minoli, Lorenzo, Baldanti, Fausto, Furione, Milena, Alfonsi, Enrico, Bergamaschi, Roberto, Romani, Alfredo, Piccolo, Laura, Zardini, Elisabetta, Bastianello, Stefano, Pichiecchio, Anna, Ferrante, Pasquale, Delbue, Serena, Franciotta, Diego, Bono, Giorgio, Ceroni, Mauro. Pages: 882-889
>
Show/Hide Abstract
Objectives: Postinfectious neurologic syndromes (PINSs) of the CNS include heterogeneous disorders, sometimes relapsing. In this study, we aimed to a) describe the spectrum of PINSs; b) define predictors of outcome in PINSs; and c) assess the clinical/paraclinical features that help differentiate PINSs from multiple sclerosis (MS).Methods: In this prospective cohort study, adult inpatients with PINSs underwent extensive diagnostic assessment and therapeutic protocols at inclusion and during a minimum 2-year follow-up. We compared them with newly diagnosed, treatment-naive patients with MS, also prospectively recruited.Results: The study sample comprised 176 patients with PINSs aged 59.9 +/- 17.25 years (range: 18-80 years) divided into 2 groups: group 1 (CNS syndromes, 64%)-encephalitis, encephalomyelitis, or myelitis; and group 2 (CNS + peripheral nervous system [PNS] syndromes, 36%)-encephalomyeloradiculoneuritis or myeloradiculoneuritis. We observed the patients for 24 to 170 months (median 69 months). Relapses, almost invariably involving the spinal cord, occurred in 30.5%. PNS involvement was an independent risk factor for relapses (hazard ratio 2.8). The outcome was poor in 43% of patients; risk factors included older age, greater neurologic disability at onset, higher serum-CSF albumin percentage transfer, myelitis, and PNS involvement. Steroid resistance occurred in 30% of the patients, half of whom responded favorably to IV immunoglobulins. Compared with MS, PINSs were characterized by older age, lower tendency to relapse, and distinct CSF findings.Conclusions: The category of PINSs should be revised: most of the clinical variants have a poor prognosis and are not readily classifiable on the basis of current knowledge. PNS involvement has a critical role in relapses, which seem to affect the spine only.(C)2013 American Academy of Neurology
|
brain [beta]-amyloid load approaches a plateau.
- Jack, Clifford, Wiste, Heather, Lesnick, Timothy, Weigand, Stephen, Knopman, David, Vemuri, Prashanthi, Pankratz, Vernon, Senjem, Matthew, Gunter, Jeffrey, Mielke, Michelle, Lowe, Val, Boeve, Bradley, Petersen, Ronald, MD, PhD. Pages: 890-896
>
Show/Hide Abstract
Objective: To model the temporal trajectory of [beta]-amyloid accumulation using serial amyloid PET imaging.Methods: Participants, aged 70-92 years, were enrolled in either the Mayo Clinic Study of Aging (n = 246) or the Mayo Alzheimer's Disease Research Center (n = 14). All underwent 2 or more serial amyloid PET examinations. There were 205 participants classified as cognitively normal and 55 as cognitively impaired (47 mild cognitive impairment and 8 Alzheimer dementia). We measured baseline amyloid PET-relative standardized uptake values (SUVR) and, for each participant, estimated a slope representing their annual amyloid accumulation rate. We then fit regression models to predict the rate of amyloid accumulation given baseline amyloid SUVR, and evaluated age, sex, clinical group, and APOE as covariates. Finally, we integrated the amyloid accumulation rate vs baseline amyloid PET SUVR association to an amyloid PET SUVR vs time association.Results: Rates of amyloid accumulation were low at low baseline SUVR. Rates increased to a maximum at baseline SUVR around 2.0, above which rates declined-reaching zero at baseline SUVR above 2.7. The rate of amyloid accumulation as a function of baseline SUVR had an inverted U shape. Integration produced a sigmoid curve relating amyloid PET SUVR to time. The average estimated time required to travel from an SUVR of 1.5-2.5 is approximately 15 years.Conclusion: This roughly 15-year interval where the slope of the amyloid SUVR vs time curve is greatest and roughly linear represents a large therapeutic window for secondary preventive interventions.(C)2013 American Academy of Neurology
|
cognitive decline in logopenic aphasia: more than losing words.
- Leyton, Cristian, Hsieh, Sharpley, Mioshi, Eneida, Hodges, John, MD, FRCP. Pages: 897-903
>
Show/Hide Abstract
Objective: To track cognitive and language changes over time in patients with logopenic (lv-PPA) and semantic (sv-PPA) variants of primary progressive aphasia (PPA).Methods: Thirteen consecutive patients with lv-PPA and 11 patients with sv-PPA underwent yearly evaluation for a mean of 3 years. Nineteen patients (11 lv-PPA, 8 sv-PPA) had Pittsburgh compound B PET scans. Outcome variables included the Mini-Mental State Examination, Addenbrooke's Cognitive Examination-revised (ACE-R) with its 5 cognitive subscores, and 3 language tasks based on single word processing. Mixed-models regressions were used to estimate the differential rate of decline between cohorts.Results: Despite equivalent level of baseline impairment, the lv-PPA cohort showed more rapid and generalized cognitive decline that involved nonverbal domains, with the majority of cases meeting criteria for dementia within 12 months. By contrast, cognitive changes in the sv-PPA cohort were slower and remained confined to verbally mediated tasks.Conclusions: Patients with lv-PPA are on the cusp of global dementia that typically develops quite rapidly, contrasting with the long period of circumscribed semantic impairment seen in patients with sv-PPA. The ACE-R appears capable of monitoring decline, which is relevant to therapeutic trials.(C)2013 American Academy of Neurology
|
total antioxidant capacity of the diet and major neurologic outcomes in older adults.
- Devore, Elizabeth, Feskens, Edith, Ikram, M., Arfan MD, PhD, Heijer, Tom, den MD, PhD, Vernooij, Meike, MD, PhD, Lijn, Fedde, Hofman, Albert, MD, PhD, Niessen, Wiro, Breteler, Monique, MD, PhD. Pages: 904-910
>
Show/Hide Abstract
Objective: To evaluate total antioxidant capacity of the diet, measured by the ferric-reducing antioxidant power (FRAP) assay, in relation to risks of dementia and stroke, as well as key structural brain volumes, in the elderly.Methods: We prospectively studied 5,395 participants in the Rotterdam Study, aged 55 years and older, who were dementia free and provided dietary information at study baseline; 5,285 individuals were also stroke free at baseline, and 462 were dementia and stroke free at the time of an MRI brain scan 5 years after baseline. Dietary data were ascertained using a semiquantitative food-frequency questionnaire, and combined with food-specific FRAP measurements from published tables; this information was aggregated across the diet to obtain "dietary FRAP scores." Multivariable-adjusted Cox proportional hazard models were used to estimate relative risks of dementia and stroke, and multivariable-adjusted linear regression was used to estimate mean differences in structural brain volumes, across tertiles of dietary FRAP scores.Results: During a median 13.8 years of follow-up, we identified approximately 600 cases each of dementia and stroke. In multivariable-adjusted models, we observed no associations between dietary FRAP scores and risk of dementia (p trend = 0.3; relative risk = 1.12, 95% confidence interval = 0.91-1.38, comparing the highest vs lowest FRAP tertiles) or risk of stroke (p trend = 0.3; relative risk = 0.91, 95% confidence interval = 0.75-1.11, comparing extreme FRAP tertiles); results were similar across subtypes of these outcomes. Dietary FRAP scores were unrelated to brain tissue volumes as well.Conclusions: Total antioxidant capacity of the diet, measured by dietary FRAP scores, does not seem to predict risks of major neurologic diseases.(C)2013 American Academy of Neurology
|
thrombogenic microvesicles and white matter hyperintensities in postmenopausal women.
- Raz, Limor, Jayachandran, M., Tosakulwong, Nirubol, Lesnick, Timothy, Wille, Samantha, Murphy, Matthew, Senjem, Matthew, Gunter, Jeffrey, Vemuri, Prashanthi, Jack, Clifford, Miller, Virginia, Kantarci, Kejal, MD, MS. Pages: 911-918
>
Show/Hide Abstract
Objective: To determine the association of conventional cardiovascular risk factors, markers of platelet activation, and thrombogenic blood-borne microvesicles with white matter hyperintensity (WMH) load and progression in recently menopausal women.Methods: Women (n = 95) enrolled in the Mayo Clinic Kronos Early Estrogen Prevention Study underwent MRI at baseline and at 18, 36, and 48 months after randomization to hormone treatments. Conventional cardiovascular risk factors, carotid intima-medial thickness, coronary arterial calcification, plasma lipids, markers of platelet activation, and thrombogenic microvesicles were measured at baseline. WMH volumes were calculated using a semiautomated segmentation algorithm based on fluid-attenuated inversion recovery MRI. Correlations of those parameters with baseline WMH and longitudinal change in WMH were adjusted for age, months past menopause, and APOE [epsilon]4 status in linear regression analysis.Results: At baseline, WMH were present in all women. The WMH to white matter volume fraction at baseline was 0.88% (0.69%, 1.16%). WMH volume increased by 122.1 mm3 (95% confidence interval: -164.3, 539.5) at 36 months (p = 0.003) and 155.4 mm3 (95% confidence interval: -92.13, 599.4) at 48 months (p < 0.001). These increases correlated with numbers of platelet-derived and total thrombogenic microvesicles at baseline (p = 0.03).Conclusion: Associations of platelet-derived, thrombogenic microvesicles at baseline and increases in WMH suggest that in vivo platelet activation may contribute to a cascade of events leading to development of WMH in recently menopausal women.(C)2013 American Academy of Neurology
|
long-term outcome in stroke patients treated with iv thrombolysis.
- Gensicke, Henrik, Seiffge, David, Polasek, Andrea, Peters, Nils, Bonati, Leo, Lyrer, Philippe, Engelter, Stefan. Pages: 919-925
>
Show/Hide Abstract
Objectives: Data on long-term outcome after IV thrombolysis (IVT) are sparse. Our goals were to 1) estimate annual survival, and 2) evaluate determinants for an unfavorable long-term outcome after IVT for stroke.Methods: This observational study is based on the IVT registry of the University Hospital Basel. A structured telephone interview was used to ascertain information about long-term outcome (1 year to 10 years after IVT). Primary outcome parameters were 1) death and 2) excellent outcome (modified Rankin Scale scores 0 and 1). Kaplan-Meier survival estimates were calculated. Uni- and multivariate logistic regression analyses were performed to identify variables independently determining long-term outcome.Results: Two hundred fifty-seven IVT-treated stroke patients were eligible for analysis. Median time of follow-up was 3.0 years (interquartile range 1.0-5.0). Probability of surviving after IVT was 76% after 1 year, 66% after 3 years, and 53% after 4 years. After a median of 3 years, 37% of patients had an excellent outcome. Independent predictors for unfavorable long-term outcome were advanced age (odds ratio [OR] 1.030, 95% confidence interval [CI] 1.002-1.060, p = 0.036), higher stroke severity (OR 1.100, 95% CI 1.012-1.196, p = 0.026), unfavorable 3-month outcome (OR 6.767, 95% CI 3.391-13.503, p < 0.001), and occurrence of epileptic seizures (OR 4.899, 95% CI 1.349-17.793, p = 0.016). Intracranial hemorrhage, comorbidity, sex, initial glucose or C-reactive protein levels, and stroke etiology did not independently influence long-term outcome.Conclusion: At 3 years after IVT, approximately 1 of 3 stroke patients had an excellent outcome, and 1 of 3 had died. Epileptic seizures seem to have an unfavorable effect on long-term outcome via a mechanism that remains to be clarified.(C)2013 American Academy of Neurology
|
corticobulbar tract changes as predictors of dysarthria in childhood brain injury.
- Liegeois, Frederique, Tournier, Jacques-Donald, Pigdon, Lauren, Connelly, Alan, Morgan, Angela. Pages: 926-932
>
Show/Hide Abstract
Objectives: To identify corticobulbar tract changes that may predict chronic dysarthria in young people who have sustained a traumatic brain injury (TBI) in childhood using diffusion MRI tractography.Methods: We collected diffusion-weighted MRI data from 49 participants. We compared 17 young people (mean age 17 years, 10 months; on average 8 years postinjury) with chronic dysarthria who sustained a TBI in childhood (range 3-16 years) with 2 control groups matched for age and sex: 1 group of young people who sustained a traumatic injury but had no subsequent dysarthria (n = 15), and 1 group of typically developing individuals (n = 17). We performed tractography from spherical seed regions within the precentral gyrus white matter to track: 1) the hand-related corticospinal tract; 2) the dorsal corticobulbar tract, thought to correspond to the lips/larynx motor representation; and 3) the ventral corticobulbar tract, corresponding to the tongue representation.Results: Despite widespread white matter damage, radial (perpendicular) diffusivity within the left dorsal corticobulbar tract was the best predictor of the presence of dysarthria after TBI. Diffusion metrics in this tract also predicted speech and oromotor performance across the whole group of TBI participants, with additional significant contributions from ventral speech tract volume in the right hemisphere.Conclusion: An intact left dorsal corticobulbar tract seems crucial to the normal execution of speech long term after acquired injury. Examining the speech-related motor pathways using diffusion-weighted MRI tractography offers a promising prognostic tool for people with acquired, developmental, or degenerative neurologic conditions likely to affect speech.(C)2013 American Academy of Neurology
|
octanoic acid in alcohol-responsive essential tremor: a randomized controlled study.
- Haubenberger, Dietrich, McCrossin, Gayle, Lungu, Codrin, Considine, Elaine, Toro, Camilo, Nahab, Fatta, Auh, Sungyoung, Buchwald, Peter, Grimes, George, Starling, Judith, Potti, Gopal, Scheider, Linda, Kalowitz, Daniel, Bowen, Daniel, Carnie, Andrea, Hallett, Mark. Pages: 933-940
>
Show/Hide Abstract
Objective: To assess safety and efficacy of an oral, single, low dose of octanoic acid (OA) in subjects with alcohol-responsive essential tremor (ET).Methods: We conducted a double-blind, placebo-controlled, crossover, phase I/II clinical trial evaluating the effect of 4 mg/kg OA in 19 subjects with ET. The primary outcome was accelerometric postural tremor power of the dominant hand 80 minutes after administration. Secondary outcomes included digital spiral analysis, pharmacokinetic sampling, as well as safety measures.Results: OA was safe and well tolerated. Nonserious adverse events were mild (Common Terminology Criteria for Adverse Events grade 1) and equally present after OA and placebo. At the primary outcome, OA effects were not different from placebo. Secondary outcome analyses of digital spiral analysis, comparison across the entire time course in weighted and nonweighted accelerometry, as well as nondominant hand tremor power did not show a benefit of OA over placebo. The analysis of individual time points showed that OA improved tremor at 300 minutes (dominant hand, F1,16 = 5.49, p = 0.032 vs placebo), with a maximum benefit at 180 minutes after OA (both hands, F1,16 = 6.1, p = 0.025).Conclusions: Although the effects of OA and placebo at the primary outcome were not different, secondary outcome measures suggest superiority of OA in reducing tremor at later time points, warranting further trials at higher dose levels.Classification of evidence: This study provides Class I evidence that a single 4-mg/kg dose of OA is not effective in reducing postural tremor in patients with ET at a primary outcome of 80 minutes, but is effective for a secondary outcome after 180 minutes.(C)2013 American Academy of Neurology
|
postdural puncture headache in migraineurs and nonheadache subjects: a prospective study.
- van Oosterhout, W.P.J., van der Plas, A.A., van Zwet, E.W., Zielman, R., Ferrari, M.D., MD, PhD, Terwindt, G.M., MD, PhD. Pages: 941-948
>
Show/Hide Abstract
Objectives: To prospectively assess 1) the incidence and duration of postdural puncture headache (PDPH) in migraineurs and healthy subjects; 2) the associated risk factors; and 3) the risk of getting a migraine attack shortly before or after lumbar puncture (LP).Methods: As part of an extensive biochemical migraine research program, we assessed the occurrence, duration, and characteristics of PDPH in 160 migraineurs and 53 age- and sex-matched healthy controls. In addition, we evaluated potential risk factors for PDPH as well as the risk of developing a migraine attack before or after LP.Results: In total, 64 of 199 subjects (32.2%) developed PDPH. Young age, low body mass index, severe headache immediately after LP, and sitting sampling position, but not being a migraineur, increased the risk of PDPH (all p < 0.05). Duration of PDPH was prolonged by history of depression, sitting sampling position, high perceived stress during the LP procedure, and multiple LP efforts (all p < 0.05). Migraine attacks were less likely to occur before or shortly after LP.Conclusions: Migraineurs are not at increased risk of developing PDPH. PDPH duration is similar in migraineurs and age- and sex-matched controls. LP does not trigger migraine attacks, and the stress of an upcoming LP might even have a protective effect against onset of migraine attacks.(C)2013 American Academy of Neurology
|
| Global Perspectives |
cassava food toxins, konzo disease, and neurodegeneration in sub-sahara africans.
- Tshala-Katumbay, D., MD, PhD, Mumba, N., MD, PhD, Okitundu, L., Kazadi, K., MD, PhD, Banea, M., MD, PhD, Tylleskar, T., MD, PhD, Boivin, M., MPH, PhD, Muyembe-Tamfum, J.J., MD, PhD. Pages: 949-951
|
| Historical Neurology |
the history of cerebral pet scanning: from physiology to cutting-edge technology.
- Portnow, Leah, Vaillancourt, David, Okun, Michael. Pages: 952-956
>
Show/Hide Abstract
Objective: To review the discoveries underpinning the introduction of cerebral PET scanning and highlight its modern applications.Background: Important discoveries in neurophysiology, brain metabolism, and radiotracer development in the post-World War II period provided the necessary infrastructure for the first cerebral PET scan.Methods: A complete review of the literature was undertaken to search for primary and secondary sources on the history of PET imaging. Searches were performed in PubMed, Google Scholar, and select individual journal Web sites. Written autobiographies were obtained through the Society for Neuroscience Web site at www.sfn.org. A reference book on the history of radiology, Naked to the Bone, was reviewed to corroborate facts and to locate references. The references listed in all the articles and books obtained were reviewed.Results: The neurophysiologic sciences required to build cerebral PET imaging date back to 1878. The last 60 years have produced an evolution of technological advancements in brain metabolism and radiotracer development. These advancements facilitated the development of modern cerebral PET imaging. Several key scientists were involved in critical discoveries and among them were Angelo Mosso, Charles Roy, Charles Sherrington, John Fulton, Seymour Kety, Louis Sokoloff, David E. Kuhl, Gordon L. Brownell, Michael Ter-Pogossian, Michael Phelps, and Edward Hoffman.Conclusions: Neurophysiology, metabolism, and radiotracer development in the postwar era synergized the development of the technology necessary for cerebral PET scanning. Continued use of PET in clinical trials and current developments in PET-CT/MRI hybrids has led to advancement in diagnosis, management, and treatment of neurologic disorders.(C)2013 American Academy of Neurology
|
| Contemporary Issues: Innovations in Education |
should there be pediatric neurohospitalists?.
- Nash, Kendall, Josephson, S., Sun, Karen, Ferriero, Donna, MD, MS. Pages: 957-962
>
Show/Hide Abstract
Hospitalist medicine has gown rapidly over the past decade in response to increasing complexity of hospitalized patients, financial pressures, and a national call for improved quality and safety outcomes. An adult neurohospitalist model of care has recently emerged to address these factors and the need for inpatient neurologists who offer expertise and immediate availability for emergent neurologic conditions such as acute stroke and status epilepticus. Similarly, hospitalized children with acute neurologic disorders require a uniquely high level of care, which increasingly cannot be delivered by pediatric neurologists with busy outpatient practices or by pediatric hospitalists without specialized training. This perspective explores the concept of a pediatric neurohospitalist model of care, including the potential impact on quality of care, hospitalization costs, and education.(C)2013 American Academy of Neurology
|
| Clinical/Scientific Notes |
limb-girdle muscular dystrophy with [alpha]-dystroglycan deficiency and mutations in the ispd gene.
- Tasca, G., Moro, F., Aiello, C., Cassandrini, D., Fiorillo, C., Bertini, E., Bruno, C., Santorelli, F.M., Ricci, E.. Pages: 963-965
|
fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies.
- Svenningsson, Anders, MD, PhD, Dring, Ann, Fogdell-Hahn, Anna, Jones, Iwan, Engdahl, Elin, Lundkvist, Malin, Brannstrom, Thomas, MD, PhD, Gilthorpe, Jonathan. Pages: 965-967
|
| Visions |
celebration.
- Jameson, Elizabeth. Pages: 968
|
| NeuroImages |
mr spectroscopy in pediatric wernicke encephalopathy.
- Rodan, Lance, Mishra, Navin, Tein, Ingrid, MD, FRCPC. Pages: 969
|
| Resident and Fellow Section |
education research: can my electronic health record teach me something?: a multi-institutional pilot study.
- Seifan, Alon, MS, MD, Mandigo, Morgan, Price, Raymond, Galetta, Steven, Jozefowicz, Ralph, Jaffer, Amir, Symes, Stephen, Safdieh, Joseph, Isaacson, Richard. Pages: e98-e103
|
clinical reasoning: a 57-year-old man with jaw spasms.
- Mari, Zoltan, Rosenthal, Liana, Darwin, Kristin, Hallett, Mark, Jinnah, H.A., MD, PhD. Pages: e104-e107
|
teaching video neuroimages: sodium channel myotonia can present with stridor.
- Brandt-Wouters, Evelyn, Klinkenberg, Sylvia, Roelfsema, Vincent, MD, PhD, Ginjaar, Ieke, Faber, Catharina, MD, PhD, Nicolai, Joost, MD, PhD. Pages: e108
|
teaching neuroimages: pet-ct hypermetabolism paralleling muscle hyperactivity in stiff-person syndrome.
- O'Toole, Orna, Murphy, Robert, MD, PhD, Tracy, Jennifer, McKeon, Andrew. Pages: e109
|
| WriteClick: Editor's Choice |
evidence-based guideline: pharmacologic treatment of chorea in huntington disease: report of the guideline development subcommittee of the american academy of neurology.
- Suchowersky, Oksana. Pages: 970
|
antiplatelets vs anticoagulation for dissection: cadiss nonrandomized arm and meta-analysis.
- Caplan, Louis. Pages: 970-971
|